These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 211670)

  • 1. Use of interferon in cytomegalovirus infections in man.
    Cheeseman SH; Rinaldo CR; Hirsch MS
    Tex Rep Biol Med; 1977; 35():523-7. PubMed ID: 211670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections.
    Cheeseman SH; Rubin RH; Stewart JA; Tolkoff-Rubin NE; Cosimi AB; Cantell K; Gilbert J; Winkle S; Herrin JT; Black PH; Russell PS; Hirsch MS
    N Engl J Med; 1979 Jun; 300(24):1345-9. PubMed ID: 220536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient.
    Puliyanda DP; Silverman NS; Lehman D; Vo A; Bunnapradist S; Radha RK; Toyoda M; Jordan SC
    Transpl Infect Dis; 2005 Jun; 7(2):71-4. PubMed ID: 16150094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of interferon in the complex treatment of young children with cytomegalic inclusion disease].
    Kuruts VM
    Pediatr Akus Ginekol; 1971; 71(5):23-4. PubMed ID: 4340201
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of cytomegalovirus disease in renal allograft recipients.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():88-93. PubMed ID: 1725064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprophylaxis against cytomegalovirus disease.
    Adler SP
    Scand J Infect Dis Suppl; 1995; 99():105-9. PubMed ID: 8668931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytomegalovirus in liver transplantation: incidence and groups at risk].
    Schiffer V; Mentha G; Giostra E; Belli D; Le Coultre C; Rohner A
    Schweiz Med Wochenschr; 1994 Apr; 124(15):631-6. PubMed ID: 8191266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eye lesions in cytomegalovirus infection].
    Maĭchuk IuF
    Oftalmol Zh; 1981; 36(3):179-84. PubMed ID: 6168992
    [No Abstract]   [Full Text] [Related]  

  • 12. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years' experience.
    D'Agaro P; Andolina M; Burgnich P; Samar E; Campello C
    Haematologica; 2000 Nov; 85(11 Suppl):54-7. PubMed ID: 11268325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.
    Pollard RB
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S97-102. PubMed ID: 2456512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus and adenovirus infections and diseases among 75 paediatric unrelated allogeneic bone marrow transplant recipients.
    Morfin F; Boucher A; Najioullah F; Bertrand Y; Bleyzac N; Poitevin-Later F; Bienvenu F; Simonet V; Galambrun C; Philippe N; Aymard M; Thouvenot D; Souillet G
    J Med Virol; 2004 Feb; 72(2):257-62. PubMed ID: 14695667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.
    Danziger-Isakov LA; DelaMorena M; Hayashi RJ; Sweet S; Mendeloff E; Schootman M; Huddleston CB; DeBaun MR
    Transplantation; 2003 May; 75(9):1538-43. PubMed ID: 12792511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.
    Prentice HG; Kho P
    Bone Marrow Transplant; 1997 Jan; 19(2):135-42. PubMed ID: 9116610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.